RxDoctor Payments Data

Salvatore Gaudino, DPM

Foot Surgery · Brooklyn, NYNPI 1053402438

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Paratek Pharmaceuticals, Inc. at 30.9% of the total. Reporting peaked in 2022 at $1,220 and has fallen 59.8% since, to $491 in 2024.

$3,558in general payments, 2019–2025

Across 114 payments — averaging $31.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paratek Pharmaceuticals, Inc.$1K
  • Nevro Corp.$1K
  • Orthofix Medical, Inc.$571
  • Amgen$242
  • Paragon 28, Inc.$176
  • Arteriocyte Medical Systems, Inc.$100
  • plus $320 from 8 others

What the payments were for

  • Food & beverage$3,558100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,558 in reported general payments places this provider in the 80th percentile of 294 foot surgery providers in New York.

See all foot surgery providers in New York

Medicare billing

Part B allowed, 2024
$7,417
Medicare patients
25
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ketoconazole40$1,864

Paid to pharmacies, not to this prescriber.

Other foot surgery in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →